Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study. Romero Riquelme MA, Aspas Requena G, Lloret-Madrid P, Gil C, et al. Am J Hematol 2026;101:2812-2826.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Romero Riquelme MA, Aspas Requena G, Lloret-Madrid P, Gil C, et al. Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study. Am J Hematol 2026;101:2812-2826.
PMID: 42671173